Literature DB >> 11847947

Agranulocytosis associated with initiation of famotidine therapy.

Esther-Lee Marcus1, A Mark Clarfield, Yosef Kleinman, Helena Bits, David Darmon, Nael Da'as.   

Abstract

OBJECTIVE: To report a case of agranulocytosis associated with initiation of famotidine. CASE
SUMMARY: An 87-year-old white man was admitted to the internal medicine department of an acute care hospital because of fever and agranulocytosis (granulocyte count 0). Eight days prior to admission, famotidine therapy had been initiated. Famotidine was discontinued and granulocyte-macrophage colony stimulating factor was administered, with concomitant recovery of the granulocyte count and subsequent development of a leukemoid reaction. DISCUSSION: According to the Naranjo probability scale, famotidine was the probable cause of agranulocytosis. This is a rare adverse effect of this medication; only a few other cases have been reported.
CONCLUSIONS: Although agranulocytosis is a rare adverse effect of famotidine, the pharmacist and physician should be aware of this potentially fatal event. If any patient treated with famotidine develops fever, the clinician should consider, among other things, performing a white blood cell count.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11847947     DOI: 10.1345/aph.1A045

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  1 in total

1.  Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

Authors:  Heidrun Appl; Tobias Holzammer; Stefan Dove; Ekkehard Haen; Andrea Strasser; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-28       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.